Aki Nakai
Mukogawa Women's University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Aki Nakai.
European Journal of Clinical Pharmacology | 1992
Mayumi Nishikata; Akikazu Nomura; Ken Iseki; Katsumi Miyazaki; Aki Nakai; Hitomi Fushida; Keishiro Miyake; Takaichi Arita
SummaryThe pharmacokinetics of a single oral dose of 20 mg (+)-, (-)- and racemic homochlorcyclizine (HCZ) have been studied in humans. The formation of the quarternary ammonium-linked glucuronide was an important metabolic pathway, and the metabolic process was enantioselective as a result of differing urinary excretion rates of (+)-, (-)- and racemic glucuronide.There were significant differences between (+)-, (-) and racemic HCZ in AUC (0-14 h) and plasma protein binding, but all HCZ enantiomers were slowly absorbed and eliminated (elimination half-lives about 11 h).The results shows help to establish a more efficient dosage regimen for HCZ therapy.
Journal of Chromatography B: Biomedical Sciences and Applications | 1993
Mayumi Nishikata; Aki Nakai; Hitomi Fushida; Keishiro Miyake; Takaichi Arita; Ken Iseki; Katsumi Miyazaki; Akikazu Nomura
A method is described for the simultaneous determination of (+)- and (-)-homochlorcyclizine (HCZ) in human urine by high-performance liquid chromatography on a chiral stationary phase of ovomucoid-bonded silica. The pH of the buffer and organic modifier in the mobile phase markedly affected the chromatographic separation. A mobile phase of methanol-0.02 M acetate buffer (pH 4.7) (25:75,v/v) at a flow-rate of 1.0 ml/min was used for the urine assays. The ultraviolet absorption was monitored at 240 nm, and diphenhydramine was employed as the internal standard for the quantitation. (+)-HCZ, (-)-HCZ and the internal standard were eluted at retention times of 15, 25 and 8 min, respectively. The limit of determination for HCZ enantiomers was ca. 50 ng/ml of urine. One of the metabolites in human urine, which was a quaternary ammonium-linked glucuronide, could also be determined in a manner similar to unchanged HCZ after beta-glucuronidase hydrolysis. A pharmacokinetic study was conducted with three healthy volunteers, who each received a single oral dose of racemic HCZ (20 mg). Distinct differences were found between the two enantiomers, particularly in the metabolic process, that is, the urinary excretion as (-)-HCZ-glucuronide within 48 h was ca. four times higher than that of the (+)-isomer. This method should be very useful for enantioselective pharmacokinetic studies of HCZ.
Journal of Pharmacy and Pharmacology | 1994
Mayumi Nishikata; Aki Nakai; Hitomi Fushida; Keishiro Miyake; Takaichi Arita; Ken Iseki; Katsumi Miyazaki
Abstract— Concentrations of homochlorcyclizine enantiomers in blood, urine, and tissues of the liver, lung, kidney, brain, heart, spleen, intestine and stomach of rats after drug administration were determined by high‐performance liquid chromatography on a chiral stationary phase. After intravenous administration (10 mg kg−1), homochlorcyclizine was rapidly distributed in many tissues, with the highest concentration in lung. No differences were found between enantiomers in blood concentrations. After oral administration (50 mg kg−1), the concentrations of the (+)‐isomer in nearly all tissues were higher than those of the (–)‐isomer. The AUC0‐x values of the (+)‐ and (–)‐isomers differed significantly. The absorption of racemic homochlorcyclizine from rat small intestine was not enantioselective. These results suggested that the different concentrations between enantiomers after oral administration were not caused by enantioselective absorption or distribution but rather by preferential first‐pass metabolism of the (–)‐isomer in the liver. The enantioselectivity of metabolism was also demonstrated by in‐vitro experiments.
Biological & Pharmaceutical Bulletin | 2002
Kenji Matsuyama; Kimiko Nakagawa; Aki Nakai; Yuriko Konishi; Mayumi Nishikata; Hiromi Tanaka; Takahiro Uchida
Chemical & Pharmaceutical Bulletin | 1997
Takahiro Uchida; Kazushi Yoshida; Yoichi Nakada; Noriko Nagareya; Yuriko Konishi; Aki Nakai; Mayumi Nishikata; Kenji Matsuyama
Biological & Pharmaceutical Bulletin | 1996
Aki Nakai; Mayumi Nishikata; Kenji Matsuyama; Masataka Ichikawa
Biological & Pharmaceutical Bulletin | 1997
Aki Nakai; Mayumi Nishikata; Takahiro Uchida; Masataka Ichikawa; Kenji Matsuyama
Chemical & Pharmaceutical Bulletin | 1992
Mayumi Nishikata; Aki Nakai; Hitomi Fushida; Keishiro Miyake; Takaichi Arita; Satomi Kitagawa; Masaru Kunitomo; Ken Iseki; Katsumi Miyazaki
Biological & Pharmaceutical Bulletin | 1994
Mayumi Nishikata; Aki Nakai; Hitomi Fushida; Keishiro Miyake; Takaichi Arita; Ken Iseki; Katsumi Miyazaki
Pharmacy and Pharmacology Communications | 1997
Takahiro Uchida; K. Yamabe; Mayumi Nishikata; Aki Nakai; Noriko Nagareya; Yuriko Konishi; Kenji Matsuyama